| Guardant Health Maps Cautious Plans For Blood-Based Cancer Screening | Alex Lash | 06/03/16 | San Francisco |
| Armed With Patent, Foundation Med Sues Diagnostic Rival Guardant | Alex Lash | 05/18/16 | Boston |
| Foundation Med Gets U.S. Patent For Cancer Analysis | Alex Lash | 05/17/16 | Boston |
| East Coast Biotech Roundup: Homology, Biogen, Intellia & More | Ben Fidler | 05/05/16 | Boston |
| West Coast Bio Roundup: Illumina, CRISPR, Orexigen, Ambry & More | Alex Lash | 03/11/16 | San Francisco |
| Blood Simple? Grail’s Cancer Screening Quest Faces Tough Questions | Alex Lash | 02/04/16 | National |
| East Coast Biotech Roundup: Alkermes, Zafgen, Snowmaggedon & More | Ben Fidler | 01/22/16 | Boston |
| Exosome Diagnostics Closes $60M Series B for Liquid Biopsy Test | David Holley | 01/07/16 | Boston |
| With $100M, Guardant Health to Expand Reach of Blood Test for Cancer | David Holley | 01/07/16 | San Francisco |
| West Coast Biotech Roundup: Tandem, Pathway Genomics, Denali & More | Bruce V. Bigelow | 09/10/15 | San Diego |
| East Coast Biotech Roundup: Bluebird, Sarepta, Synlogic & More | Ben Fidler | 05/22/15 | Boston |
| Guardant Grabs $50M to Expand Cancer Blood Test | David Holley | 02/03/15 | San Francisco |
| Tests for Tumor DNA in Blood May Yield New Ways to Hit Cancer | Bernadette Tansey | 02/26/14 | San Francisco |
